Perioperative omega-3 fatty acids for liver surgery: A meta-analysis of randomized controlled trials

Fubin Xiao, Wei Han, PD, Qing Yue, PD, Jianji Ke, PD, Baoxing Jia, PD, *Xiaojuan Fu, *Correspondence: Xiaojuan Fu, 1 Hanyu Road, Shapingba Districion, Chongqing, 401331, P.R. China (e-mail: Wendylee3540@sina.com).

Abstract

Introduction: The effect of perioperative omega-3 fatty acids for liver surgery remained controversial. We conducted a systematic review and meta-analysis to explore the influence of omega-3 fatty acids versus placebo in patients undergoing liver surgery.

Methods: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through May 2020, and included randomized controlled trials (RCTs) assessing the effect of omega-3 fatty acids versus placebo for liver surgery. This meta-analysis was performed using the random-effect model.

Results: Five RCTs were included in the meta-analysis. Overall, compared with control group for liver surgery, omega-3 fatty acids were associated with substantially reduced incidence of infection (odd ratio [OR]=0.56; 95% confidence interval [CI]=0.34–0.91; P=0.02), but revealed no remarkable influence on complications (OR=0.60; 95% CI=0.29–1.24; P=0.17), mortality (OR=0.76; 95% CI=0.06–9.37; P=0.83), liver failure (OR=0.72; 95% CI=0.10 to 5.00; P=0.74), biliary leakage (OR=1.24; 95% CI=0.41 to 3.76; P=0.70), bleeding (OR=1.76; 95% CI=0.63–4.95; P=0.28), or ileus (OR=0.39; 95% CI=0.07–2.05; P=0.27).

Conclusion: Perioperative omega-3 fatty acids may be beneficial to reduce the incidence of infection after liver surgery.

Abbreviations: CI = confidence interval, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, RCTs = randomized controlled trials, SMD = standard mean difference.

Keywords: liver surgery, omega-3 fatty acids, randomized controlled trials

1. Introduction

Omega-3 fatty acids are the essential nutritional components in the human body, and are associated with extraordinarily low incidence of coronary heart disease. The liver is known as a central metabolic target of omega-3 fatty acids, and there is growing evidence showing the beneficial effects of omega-3 fatty acids on fatty liver and metabolic syndrome. Omega-3 fatty acids were documented to lower intrahepatic lipid contents and mitigate inflammatory responses in the liver.

Liver surgery may result in an amplified ischemia-reperfusion injury and impaired regeneration. Significant liver protection of ischemia-reperfusion injury and improved regeneration was observed after the treatment with omega-3 fatty acids in the animal models of hepatic surgery. For instance, intravenous administration of single dose of omega-3 fatty acids before liver ischemia could mitigate the production of reactive oxygen species (ROS), which was mediated via the GPR120 receptor located on hepatic Kupffer cells. The protective effect of omega-3 fatty acids on liver function was associated with the enhancement of hepatic beta oxidation, significant reduction of endogenous lipid production and pro-inflammatory molecules.

The efficacy of omega-3 fatty acids for liver surgery remained not fully established, and several studies reported the conflicting results. With accumulating evidence, we therefore performed this meta-analysis of randomized controlled trials (RCTs) to explore the efficacy of omega-3 fatty acids for liver surgery.

2. Materials and methods

Ethical approval and patient consent were not required because this was a meta-analysis of previously published studies. This meta-analysis is conducted and reported in adherence to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses).

2.1. Search strategy and study selection

Two investigators have independently searched the following databases (inception to May 2020): PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases. The electronic search strategy was conducted using the following keywords: “omega-3 fatty acids,” “liver” or “hepatic,” and “surgery” or “operation,” and “cancer” or “tumor.” We also checked the reference lists of the screened full-text studies to identify other potentially eligible trials.

The inclusive selection criteria were as follows: study design was RCT; patients underwent the surgery due to liver tumor;
intervention treatments were perioperative omega-3 fatty acids versus placebo.

2.2. Data extraction and outcome measures

We extracted the following information: author, number of patients, age, male, body mass index, and detail methods in each group, and so on. Data were extracted independently by 2 investigators, and discrepancies were resolved by consensus. We also contacted the corresponding author to obtain the data when necessary. The primary outcomes were infection and complications. Secondary outcomes included mortality, liver failure, biliary leakage, bleeding, and ileus.

2.3. Assessment for risk of bias

The risk of bias tool was used to assess the quality of individual studies in accordance with the Cochrane Handbook for Systematic Reviews of Interventions, and the following sources of bias were considered: selection bias, performance
Table 1
Characteristics of included studies.

| No. | Author          | Omega-3 fatty acids group | Control group |
|-----|-----------------|----------------------------|---------------|
|     | No. | Age, y        | Male (n) | Body mass index, kg/cm² | Methods | No. | Age, y        | Male (n) | Body mass index, kg/cm² | Methods |
| 1   | Linecker 2020  | 132                        | 62       | 24 (22–27)               | One dose of Omegaven (100 mL) contains 10 g of highly refined fish oil mainly containing eicosapentaenoic and docosahexaenoic acid before liver surgery | 129 | 60 (50–68)     | 67       | 25 (23–28)               | Placebo |
| 2   | Zhang et al, 2017 [15] | 157 | — | — | 10% n-3 Fatty acid for 5 consecutive days postoperatively | 155 | — | — | — | Placebo |
| 3   | Watson et al, 2016 [16] | 43 | — | — | Eicosapentaenoic acid 2 g taken as 2 gastroresistant capsules twice daily after the surgery | 45 | — | — | — | Placebo |
| 4   | Seguin et al, 2016 [17] | 18 | 65±8 | 17 | 26.9±4.5 | Oral impact 3 times daily for 7 days before and 3 days after surgery | 17 | 68±6 | 14 | 28.0±4.6 | Placebo |
| 5   | Kazuhiro 2011   | 13 | 67.5±11.3 | 10 | 23.6±3.8 | 750 mL for n-3 fatty acid, arginine, and nucleic acid per day for 5 days before the hepatectomy | 13 | 61.5±10.2 | 8 | 21.5±4.4 | Placebo |

Data are presented as mean ± standard deviation (SD) or median (IQR).

Figure 2. Risk of bias assessment. (A) Authors’ judgments about each risk of bias item for each included study. (B) Authors’ judgments about each risk of bias item presented as percentages across all included studies.
bias, attrition bias, detection bias, reporting bias, and other potential sources of bias. The overall risk of bias for each study was evaluated and rated: low, unclear, and high.\(^{[21]}\) Two investigators assessed the quality of included studies. Any discrepancy was solved by consensus.

### 2.4. Statistical analysis

We estimated the odd ratio (OR) with 95\% confidence interval (CI) for dichotomous outcomes. The random-effects model was used regardless of heterogeneity. Heterogeneity was reported using the \( I^2 \) statistic, and \( I^2 > 50\% \) indicated significant heterogeneity.\(^{[19,22]}\) Whenever significant heterogeneity was present, we searched for potential sources of heterogeneity via omitting one study in turn or performing the subgroup analysis. All statistical analyses were performed using Review Manager Version 5.3 (The Cochrane Collaboration, Software Update, Oxford, UK).

### 3. Results

#### 3.1. Literature search, study characteristics and quality assessment

A detailed flowchart of the search and selection results was shown in Figure 1. A total number of 508 potentially relevant articles were identified initially and 5 RCTs were finally included in the meta-analysis.\(^{[5,13–17,23]}\)

The baseline characteristics of the five eligible RCTs were summarized in Table 1. The 5 studies were published between 2011 and 2020, and total sample size is 722. Among the 5 studies included here, 4 studies reported infection and complications,\(^{[5,15,17,23]}\) as well as 2 studies reported mortality, liver failure, biliary leakage, bleeding, and ileus.\(^{[5,15]}\)

#### 3.2. Assessment of risk of bias

Risk of bias analysis (Fig. 2) showed that 1 study had high risk of attrition bias,\(^{[16]}\) but all RCTs generally had high quality.

#### 3.3. Primary outcomes: infection and complications

These outcome data were analyzed with the random-effects model, and compared to control group for liver surgery, omega-3 fatty acids substantially reduced the incidence of infection (\( OR = 0.56; 95\% \text{ CI } = 0.34–0.91; P = .02 \)) with no heterogeneity among the studies (\( I^2 = 0\% \), heterogeneity \( P = .40 \)) (Fig. 3A), but showed no obvious impact on complications (\( OR = 0.60; 95\% \text{ CI } = 0.29–1.24; P = .17 \)) with significant heterogeneity among the studies (\( I^2 = 67\% \), heterogeneity \( P = .03 \)) (Fig. 4A).
3.4. Sensitivity analysis

Figure 3B and 4B showed the funnel plots for studies reporting infection and complications, separately. These were not symmetrical, indicating significant heterogeneity. Significant heterogeneity remained for complications. After excluding the study conducted by Linecker et al.,[5] omega-3 fatty acids were associated with significantly reduced complications than placebo after liver surgery (OR = 0.41; 95% CI = 0.27–0.64; P < .0001), and no heterogeneity remained (I² = 0%, heterogeneity P = .90).

3.5. Secondary outcomes

In comparison with control group for liver surgery, omega-3 fatty acids had no notable effect on mortality (OR = 0.76; 95% CI = 0.06–9.37; P = .83; Fig. 5), liver failure (OR = 0.72; 95% CI = 0.10–5.00; P = .74; Fig. 6), biliary leakage (OR = 1.24; 95% CI = 0.41 to 3.76; P = .70; Fig. 7), bleeding (OR = 1.76; 95% CI = 0.63–4.95; P = .28; Fig. 8), or ileus (OR = 0.39; 95% CI = 0.07–2.05; P = .27; Fig. 9).
4. Discussion

In various animal studies, the beneficial effects of omega-3 fatty acids were observed to alleviate ischemia-reperfusion injury and promote liver regeneration. Previous studies also revealed the anti-cancer effects of omega-3 fatty acids. However, in this meta-analysis, we included 5 RCTs involving 722 patients and found that perioperative omega-3 fatty acids was only associated with substantially reduced incidence of infection after the liver surgery, but had no obvious impact on the total complications, mortality, liver failure, biliary leakage, bleeding, or ileus.

Regarding the sensitivity analysis, there was significant heterogeneity for the complications. Among the 4 included RCTs, only the study conducted by Linecker et al reported the 1 dose of omega-3 fatty acids before the surgery, whereas other studies reported the continuous use of omega-3 fatty acids for several days before and/or after the surgery. After excluding the study conducted by Linecker et al, omega-3 fatty acids could significantly reduce complications than placebo after liver surgery (OR = 0.41; 95% CI = 0.27–0.64; \(P < .0001\)), and no heterogeneity was observed among the remaining studies (\(I^2 = 0\%\), heterogeneity \(P = .90\)). These indicated that continuous use of omega-3 fatty acids could significantly reduce complications after liver surgery.
omega-3 fatty acids for several days before and/or after the surgery had significantly better efficacy to reduce the rate of complications than only 1 dose. Oral supplementation of omega-3 fatty acids for 4 weeks was documented to reduce intrahepatic lipid content in preparation for bariatric surgery and living donor liver transplantation. Parenteral use of omega-3 fatty acids supplementation for 7 consecutive days was associated with the reduction in infectious complications and hospitalization time after liver transplantation. Another 3 studies also demonstrated the positive effects of omega-3 fatty acids on liver regeneration, mortality and length of hospital stay after liver surgery. A 5-day course of postoperative intravenous supplementation of omega-3 fatty acids resulted in a reduction of total postoperative complications and length of hospital stay after hepatectomy. These suggested that the protective effect of omega-3 fatty acids for liver surgery was affected by the forms, doses, and duration of omega-3 fatty acids.

Omega-3 fatty acid, a fish oil, was enriched in eicosapentaenoic acid and docosahexaenoic acid. It showed the anti-inflammatory effect through regulating the arachidonic acid pathway and producing 3-series prostaglandins, thromboxanes, and 5-series leukotrienes. These subsequently reduced the proinflammatory cytokines including interleukin (IL)-6, IL-8, and tumor necrosis factor-α. In addition, omega-3 fatty acid was documented to change membrane fluidity through the regulation of gene transcription such as sterol regulatory element-binding protein-1, protein acylation, and calcium release.

This meta-analysis had several potential limitations. First, our analysis was based on 5 RCTs, and all of them had a relatively small sample size (n < 100). Overestimation of the treatment effect was more likely in smaller trials compared with larger samples. Next, there was significant heterogeneity, which may be caused by different doses, forms, and duration of omega-3 fatty acids. Finally, it was not feasible to perform the subgroup analysis based on different dosages and treatment time for drug administration.

5. Conclusions
Omega-3 fatty acids may benefit to reduce the incidence of infection after liver surgery.

Author contributions
FB.X and W.H were involved in the acquisition of data. Q.Y and J.J.K analyzed and interpreted the data. BX.J drafted the article. X.J.F designed the paper and approved the version to be published. All authors approved this version for publication.

Conceptualization: Baoxing Jia.
Data curation: Qing Yue, Baoxing Jia.
Formal analysis: Wei Han, Baoxing Jia.
Methodology: Wei Han.
Resources: Baoxing Jia.
Supervision: Jianji Ke.

References
[1] Shahidi F, Ambigaipalan P. Omega-3 polyunsaturated fatty acids and their health benefits. Ann Rev Food Sci Technol 2018;9:345–81.
[2] Jeromson S, Gallagher JI, Galloway SD, Galloway DL. Omega-3 fatty acids and skeletal muscle health. Marine Drugs 2015;13:6977–7004.
[3] Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018;7:Cd003177.
[4] Heshmati J, Morvaridzadeh M, Maroufizadeh S, et al. Omega-3 fatty acids supplementation and oxidative stress parameters: a systematic review and meta-analysis of clinical trials. Pharmaco Res 2019;149:104462.
[5] Linecker M, Botea F, Aristotele Raptis D, et al. Perioperative omega-3 fatty acids fail to confer protection in liver surgery: results of a multicentric, double-blind, randomized controlled trial. J Hepatol 2020;72:498–505.
[6] Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science (New York, NY) 1987;237:885–8.
[7] Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017;67:829–46.
[8] Okada L, Oliveira CP, Stefano JT, et al. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight. Clin Nutr (Edinburgh, Scotland) 2018;37:1474–84.
[9] Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol 2013;75:645–62.
[10] Vetelainen R, van Vliet A, Gouma DJ, van Gulik TM. Steatosis as a risk factor in liver surgery. Ann Surg 2007;245:20-30.
[11] Marsman HA, de Graaf W, Heger M, et al. Hepatic regeneration and functional recovery following partial liver resection in an experimental model of hepatic steatosis treated with omega-3 fatty acids. Br J Surg 2013;100:674–83.
[12] Linecker M, Limani P, Kambakamba P, et al. Omega-3 fatty acids protect fatty and lean mouse livers after major hepatectomy. Ann Surg 2017;266:324–32.
[13] Raptis DA, Limani P, Jang JH, et al. GPR120 on Kuffer cells mediates hepatoprotective effects of (3-fatty acids. J Hepatol 2014;66:625–32.
[14] Di Minno MN, Russolillo A, Lupoli R, Ambrosino A, Di Minno A, Tarantino G. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. World J Gastroenterol 2012;18:5839–47.
[15] Zhang B, Wei G, Li R, et al. n-3 fatty acid-based parenteral nutrition improves postoperative recovery for cirrhotic patients with liver cancer: a randomized controlled clinical trial. Clin Nutr (Edinburgh, Scotland) 2017;36:1239–44.
[16] Watson H, Cockbain AJ, Spencer J, et al. Measurement of red blood cell eicosapentaenoic acid (EPA) levels in a randomised trial of EPA in patients with colorectal cancer liver metastases. Prostaglandins Leukot Essent Fatty Acids 2016;115:60–6.
[17] Seguin P, Locher C, Boudjema K, et al. Effect of a perioperative nutritional supplementation with oral impact in patients undergoing hepatic surgery for liver cancer: a prospective, placebo-controlled, randomized, double-blind study. Nutr Cancer 2016;68:464–72.
[18] Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
[19] Zhao J, Huang W, Zhang S, et al. Efficacy of glutathione for patients with cystic fibrosis: a meta-analysis of randomized-controlled studies. Am J Rhinol Allergy 2019;1945892419878315.
[20] G.S. Higgins JPT, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration (2011. Available from www.cochrane-handbook.org).
[21] Higgins JP, Altman DG, Gotzsche PC, et al. G. Cochrane Bias Methods, The Cochrane Collaboration Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration 2011;9:5398.
[22] Higgs JP, Thompson SG. Counting heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
[23] Mikagi K, Kawahara R, Kinoshita H, Aoyagi S. Preoperative immunonutrition in patients undergoing liver resection: a prospective randomized trial. Kurume Med J 2011;58:1–8.
[24] El-Badry AM, Moritz W, Contaldo C, Tian Y, Graf R, Clavien PA. Immunonutrition in patients undergoing liver resection: a prospective randomized trial. Clin Nutr (Edinburgh, Scotland) 2013;31:870–81.
[25] Eliseo D, Velotti F. Omega-3 fatty acids and cancer cell cytotoxicity: implications for multi-targeted cancer therapy. J Clin Med 2016;5:28–35.
[26] Inoue-Yamauchi A, Itagaki H, Oda H. Eicosapentaenoic acid attenuates ischemia-reperfusion liver injury in rats. World J Gastroenterol 2012;18:5839–47.
[27] Iannelli A, Martini F, Schneck AS, et al. Preoperative 4-week oral supplementation of omega-3 fatty acids fail to confer protection in liver surgery: results of a multicentric, double-blind, randomized controlled trial. J Hepatol 2020;72:498–505.
[28] Torlendir L, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, Pascoe WS. Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science (New York, NY) 1987;237:885–8.
[29] Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017;67:829–46.
[30] Okada L, Oliveira CP, Stefano JT, et al. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight. Clin Nutr (Edinburgh, Scotland) 2018;37:1474–84.
[31] Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol 2013;75:645–62.
Clavien PA, Oberroller CE, Raptis DA, Lehmann K, Rickenbacher A, El-Badry AM. What is critical for liver surgery and partial liver transplantation: size or quality? Hepatology (Baltimore, Md) 2010; 52:715–29.

Zhu XH, Wu YF, Qiu YD, Jiang CP, Ding YT. Liver-protecting effects of omega-3 fish oil lipid emulsion in liver transplantation. World J Gastroenterol 2012;18:6141–7.

Gong Y, Liu Z, Liao Y, et al. Effectiveness of ω-3 polyunsaturated fatty acids based lipid emulsions for treatment of patients after hepatectomy: a prospective clinical trial. Nutrients 2016;8:

Ibrahim ES, Saleh SM, El hoseeny M, El shaarawy A. Effect of omega-3 on hepatic regeneration in adult living donors undergoing hepatic resections for liver transplantation: a randomized controlled trial. J Crit Care 2016;31:157–62.

Lee S, Gura KM, Puder M. Omega-3 fatty acids and liver disease. Hepatology (Baltimore, Md) 2007;45:841–5.

Tsou SS, Chiu WC, Yeh CL, Hou YC, Yeh SL. Effects of omega-3 fatty acids on inflammatory mediators and splenocyte cytokine mRNA expressions in rats with polymicrobial sepsis. Nutrition (Burbank, Los Angeles County, Calif) 2008;24:484–91.

Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology (Baltimore, Md) 2003;38:1529–39.